1-(2-乙炔基-1-哌啶基)乙酮 | 130609-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-乙炔基-1-哌啶基)乙酮
• 英文名称: 1-(2-ethynylpiperidin-1-yl)ethan-1-one
• 英文别名: 1-(2-Ethynyl-piperidin-1-yl)-ethanone；Piperidine,1-acetyl-2-ethynyl-；1-(2-ethynylpiperidin-1-yl)ethanone
• CAS: 130609-74-4
• 化学式: C₉H₁₃NO
• mdl: MFCD09263914
• 分子量: 151.208
• InChiKey: GTJWFTSLKATWSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-乙炔基-1-哌啶基)乙酮 、 N-(3-amino-7-bromo-4-(2-chloro-5-fluorophenoxy)-1-methyl-1H-indazol-5-yl)-3-fluoro-5-(trifluoromethyl)benzamide 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(7-((1-acetylpiperidin-2-yl)ethynyl)-3-amino-4-(2-chloro-5-fluorophenoxy)-1-methyl-1H-indazol-5-yl)-3-fluoro-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE PI3KΑ

  摘要：

  The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.

  公开号：

  WO2023239846A1
• 作为产物：
  描述：

  1-乙酰哌啶 在 tetrabutylammonium tetrafluoroborate 作用下， 生成 1-(2-乙炔基-1-哌啶基)乙酮
  参考文献：
  名称：

  Resolved pyrrolidine, piperidine, and perhydroazepine analogs of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide

  摘要：

  A series of conformationally restricted analogues of the partial muscarinic agonist N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM 5; 1) was synthesized. Three of the racemic derivatives were resolved into the enantiomers. The compounds were investigated for muscarinic and antimuscarinic activity in the isolated guinea pig ileum. They were found to be fairly potent muscarinic antagonists or weak partial agonists. The new compounds were either equally or less potent than 1 in inhibiting (-)-[3H]-N-methylscopolamine binding in homogenates of the rat cerebral cortex. Thus, structural modifications to 1 in which the amide moiety and the methyl group in the butynyl chain have been joined to form a six- or seven-membered ring preserve affinity but abolish efficacy. The R enantiomers were found to have 14-79 times higher affinity to ileal muscarinic receptors than the respective antipodes. The enantiomeric affinity ratios were nearly identical in both preparations studied. As suggested by molecular mechanics calculations, the difference in affinity between the five-membered and the six- and seven-membered ring analogues may be rationalized in conformational terms.

  DOI：

  10.1021/jm00174a014

文献信息

• LUNDKVIST, J. R. MICHAEL;VARGAS, HUGO M.;CALDIROLA, PATRIZIA;RINGDAHL, BJ+, J. MED. CHEM., 33,(1990) N2, C. 3182-3189
  作者：LUNDKVIST, J. R. MICHAEL、VARGAS, HUGO M.、CALDIROLA, PATRIZIA、RINGDAHL, BJ+

  DOI：——

  日期：——
• Resolved pyrrolidine, piperidine, and perhydroazepine analogs of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide
  作者：J. R. Michael Lundkvist、Hugo M. Vargas、Patrizia Caldirola、Bjoern Ringdahl、Uli Hacksell

  DOI：10.1021/jm00174a014

  日期：1990.12

  A series of conformationally restricted analogues of the partial muscarinic agonist N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM 5; 1) was synthesized. Three of the racemic derivatives were resolved into the enantiomers. The compounds were investigated for muscarinic and antimuscarinic activity in the isolated guinea pig ileum. They were found to be fairly potent muscarinic antagonists or weak partial agonists. The new compounds were either equally or less potent than 1 in inhibiting (-)-[3H]-N-methylscopolamine binding in homogenates of the rat cerebral cortex. Thus, structural modifications to 1 in which the amide moiety and the methyl group in the butynyl chain have been joined to form a six- or seven-membered ring preserve affinity but abolish efficacy. The R enantiomers were found to have 14-79 times higher affinity to ileal muscarinic receptors than the respective antipodes. The enantiomeric affinity ratios were nearly identical in both preparations studied. As suggested by molecular mechanics calculations, the difference in affinity between the five-membered and the six- and seven-membered ring analogues may be rationalized in conformational terms.
• [EN] HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE PI3KΑ
  申请人：[en]SYNNOVATION THERAPEUTICS, INC.

  公开号：WO2023239846A1

  公开（公告）日：2023-12-14

  The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.